Targeting Bcl-2 with oblimersen for patients with hormone refractory prostate cancer.

Abstract

Patients with metastatic hormone refractory prostate cancer (HRPC) have limited treatment options and new therapies are needed. Advances in the understanding of the molecular mechanisms implicated in prostate cancer progression have identified many potential therapeutic gene targets including Bcl-2, an important pro-survival regulator of apoptotic cell death. Bcl-2 is overexpressed in a variety of human malignancies including prostate cancer where it has also been associated with androgen independent progression and treatment resistance. Oblimersen is a phosphorothioate antisense oligonucleotide complimentary to the Bcl-2 mRNA and a potent inhibitor of Bcl-2 expression which in pre-clinical testing can significantly enhance the therapeutic effect of chemotherapy, hormone and radiation therapy. Clinical trials evaluating oblimersen in combination with chemotherapy in a variety of cancers have shown good tolerability and promising response rates. Randomized trials are required to determine if oblimersen can enhance the effectiveness of docetaxel in patients with HRPC.

• Authors: Kim N Chi
• Journal: World journal of urology (World J Urol) Vol. 23 Issue 1 Pg. 33-7 (Feb 2005) ISSN: 0724-4983 [Print] Germany
• PMID: 15723221 (Publication Type: Journal Article, Review)

Chemical References

• Thionucleotides
• oblimersen

Topics

• Apoptosis (drug effects)
• Gene Targeting (methods)
• Genes, bcl-2 (drug effects, physiology)
• Humans
• Male
• Prostatic Neoplasms (drug therapy, metabolism, pathology)
• Thionucleotides (therapeutic use)